OBJECTIVES: The study aimed to assess the perception of postmenopausal Romanian women with hypertension and osteoporosis concerning bisphosphonate therapy and to increase the therapy adherence. METHODS: Our study included 38 postmenopausal osteoporotic women with hypertension, aged between 56 and 70 years old, on which biophosphanates therapy has been initiated. We evaluated each patient to rule out their perception concerning bisphosphonate therapy and the reasons for an eventually decreased drug compliance. The therapeutic compliance of the patients was assessed through 8-Item Morisky Medication Adherence Scale (MMAS-8). Regarding the bisphosphonate therapeutic scheme, we mention that: 16 patients began treatment with Alendronic acid 70mg per week, 10 patients with Risedronic acid 35mg per week and 12 patients with Ibandronic acid 150mg administrated monthly. RESULTS: After a 6 months period from the initiation of the therapy, 12 of the patients treated with bisphosphonates with weekly administration and 8 of the patients treated with bisphosphonates with monthly administration, didn’t follow the medical advice regarding the continuity of the drug administration. The factors associated with an increased or a decreased therapy compliance were represented by:  the frequency of drug administration, the perception of the patients on the long-term therapy, the prognosis of the disease without treatment, the medical education regarding osteoporosis and the quality of life with or without treatment. As a result of a multivariate analysis, we noticed that bisphosphonates with weekly administration were associated with decreased drug compliance. CONCLUSIONS: In our study, bisphosphonate compliance of postmenopausal osteoporotic women with hypertension was decreased, whereas a good adherence was observed for bisphosphonates with monthly administration.